Early inhibition of caspase-3 activity lessens the development of graft coronary artery disease

J Heart Lung Transplant. 2005 Jul;24(7):827-32. doi: 10.1016/j.healun.2004.05.015.

Abstract

Background: The role of apoptosis in the development of graft coronary artery disease (GCAD) is poorly understood. We have previously shown that early overexpression of the anti-apoptotic protein Bcl-2 lessens the development of GCAD. We hypothesized that early inhibition of apoptosis with a caspase-3 inhibitor would also lessen the development of GCAD.

Methods: Heterotopic heart transplantation was performed in 4 groups of rats. Donor hearts were pretreated with 50 microg DEVD-CHO, a cell-permeable caspase-3 inhibitor, or vehicle. Recipient animals were pretreated with 1.7 mg/kg intraperitoneal DEVD-CHO or vehicle. Animals were treated with 7.5 mg/kg/d cyclosporine for 10 days to prevent acute rejection. On post-operative day 90, the animals were sacrificed and the transplanted hearts were assessed morphometrically for evidence of GCAD.

Results: At 90 days, intimal proliferation was significantly higher in vehicle treated animals than in inhibitor treated animals. Moreover, the percentage of vessels with high-grade occlusion (>50%) was also lower in inhibitor treated animals.

Conclusions: Early inhibition of caspase-3 activity with cell-permeable DEVD-CHO lessens the development of GCAD. Caspase-3 inhibition may be a useful strategy for prevention of GCAD in clinical transplantation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Caspase 3
  • Caspase Inhibitors*
  • Coronary Artery Disease / prevention & control*
  • Cysteine Proteinase Inhibitors / therapeutic use*
  • Gene Expression
  • Genes, bcl-2
  • Graft Rejection / pathology
  • Graft Rejection / prevention & control*
  • Heart Transplantation*
  • Male
  • Oligopeptides / therapeutic use*
  • Rats
  • Rats, Inbred ACI

Substances

  • Caspase Inhibitors
  • Cysteine Proteinase Inhibitors
  • Oligopeptides
  • aspartyl-glutamyl-valyl-aspartal
  • Casp3 protein, rat
  • Caspase 3